Packing in endonasal surgery.
R Weber, R Keerl, F Hochapfel...
https://pubmed.ncbi.nlm.nih.gov/11562881/Actively Recruiting
Led by Maxigen Biotech Inc. · Updated on 2026-10-06
154
Participants Needed
3
Research Sites
13 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of a collagen-based absorbable nasal packing device called NasoAid compared to a synthetic nasal packing device called NasoPore. This study focuses on patients undergoing nasal surgery that requires nasal packing to control bleeding. The trial is a randomized, single-blind, multicenter study designed to determine if NasoAid is not worse than NasoPore in controlling bleeding and improving nasal outcomes. Participants will be randomly assigned to receive either NasoAid or NasoPore nasal packing at the end of their nasal surgery. The nasal packing may be trimmed during surgery to fit the nasal cavity as needed. The study includes a 12-week follow-up period with visits at 1, 2, 4, 8, and 12 weeks after surgery. Hemostasis will be assessed at 2, 12, 24, and 48 hours post-surgery. Additionally, researchers will evaluate the percentage of nasal packing material remaining at week 1, as well as perform endoscopic nasal assessments and gather patient-reported outcome measures. During the study, participants will complete various assessments including visual analog scales VAS for general assessment and product satisfaction, and symptom questionnaires like the Sino-Nasal Outcome Test-22 SNOT-22, Nasal Obstruction Symptom Evaluation NOSE, and Total Nasal Symptom Score TNSS. Safety indicators and any device-related adverse events will be monitored throughout the 12 weeks. This comprehensive evaluation aims to understand the performance, patient experiences, and safety of the two nasal packing materials.
CONDITIONS
Efficacy and Safety of NasoAid® After Nasal Surgery
L
LiRong Chen
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Maxigen Biotech Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants receive nasal packing with either NasoAid® or NasoPore at the end of their nasal surgery.
1 surgery day visit
Duration - 12 weeks
Participants attend follow-up visits at weeks 1, 2, 4, 8, and 12 after surgery for assessments including nasal endoscopy, bleeding checks, and symptom questionnaires.
5 visits over 12 weeks
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
R Weber, R Keerl, F Hochapfel...
https://pubmed.ncbi.nlm.nih.gov/11562881/Jianzhang Wang, Changping Cai, Shili Wang
https://pubmed.ncbi.nlm.nih.gov/24710428/A Valero, A M Navarro, A Del Cuvillo...
https://pubmed.ncbi.nlm.nih.gov/29345622/Michael Sommer, José W J M Geurts, Bjorn Stessel...
https://pubmed.ncbi.nlm.nih.gov/19221238/Justyna Dąbrowska-Bień, Piotr Henryk Skarżyński, Iwonna Gwizdalska...
https://pubmed.ncbi.nlm.nih.gov/29770875/Amy S Ketcham, Joseph K Han
https://pubmed.ncbi.nlm.nih.gov/20599092/Ying-Piao Wang, Mao-Che Wang, Yu-Chun Chen...
https://pubmed.ncbi.nlm.nih.gov/21292198/Gerhard Rettinger, Hanspeter Kirsche
https://pubmed.ncbi.nlm.nih.gov/17131271/Maoxiao Yan, Dandan Zheng, Ying Li...
https://pubmed.ncbi.nlm.nih.gov/25526585/Pawel Krzysztof Burduk, Malgorzata Wierzchowska, Blazej Grześkowiak...
https://pubmed.ncbi.nlm.nih.gov/27068885/Maxigen Biotech Inc.
Lead Sponsor